Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, has announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Zosano, as detailed in the company press release.
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, has announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Zosano, as detailed in the company press release.
Latham & Watkins LLP represented Zosano Pharma Corporation in the offering with a Silicon Valley-based team led by partners Kathleen Wells and Alan Mendelson with associates John Williams, Kaitlyn Fulcher, and Madelyn Tarr. Advice was also provided on regulatory matters by Washington, D.C. partner Ben Haas with San Francisco counsel Betty Pang and Washington, D.C. associatesChad Jennings, Michael Dreyfuss, and Anna-Kay Richards; on intellectual property matters by Silicon Valley partner Judith Haskowith associate Gavin Liu; and on tax matters by San Francisco partner Grace Lee with Silicon Valley associate Mi Zhou.
Catie Weckenman
Public Relations Lead – Transactions Team
LATHAM & WATKINS LLP
555 Eleventh Street, NW
Suite 1000
Washington, D.C. 20004-1304
Direct Dial: +1.202.350.5230
Fax: +1.202.637.2201
Email: catie.weckenman@lw.com
